Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.50 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | RGS12 | O14924 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | THPO | P40225 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15782855 | 0.87 | CYP1A2 (0.57) | CYP1A2CYP2C19AKR1B1NR1H4HPGD | |
| SCHEMBL14090661 | 0.86 | CYP1A2 (0.41) | CYP1A2CYP2C19NR1H4POLBALDH1A1 | |
| SCHEMBL3693386 | 0.84 | ATM (0.39) | CYP1A2CYP2C19LMNAGRIN2DGRIN3B | |
| SCHEMBL3623604 | 0.84 | CYP1A2 (0.62) | CYP1A2CYP2C19AKR1B1NR1H4HPGD | |
| SCHEMBL70565 | 0.82 | AKR1B1 (0.71) | CYP1A2CYP2C19AKR1B1HPGDHSD17B10 | |
| SCHEMBL14090658 | 0.81 | LMNA (0.58) | CYP1A2CYP2C19AKR1B1NR1H4HPGD | |
| SCHEMBL5041863 | 0.81 | CA2 (0.54) | AKR1B1NR1H4HPGDHSD17B10KDM4E | |
| Hydrochloric Acid SCHEMBL8922940 | 0.80 | AKR1B1 (0.68) | CYP1A2CYP2C19AKR1B1HPGDHSD17B10 | |
| SCHEMBL9321449 | 0.80 | AKR1B1 (0.52) | CYP1A2CYP2C19AKR1B1NR1H4HPGD | |
| SCHEMBL18116097 | 0.80 | CYP1A2 (0.57) | CYP1A2CYP2C19AKR1B1NR1H4HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2764866-A1 | Inhibitors of nedd8-activating enzyme | IP Gesellschaft für Management mbH (DE) | 2014-08-13 | — | — | EP | disclosed |
| EP-2764866-A1 | Inhibitors of nedd8-activating enzyme | IP Gesellschaft für Management mbH (DE) | 2014-08-13 | — | — | EP | disclosed |
| WO-2013021309-A1 | INTERMEDIATE AND PROCESS FOR THE PREPARATION OF A SULFONAMIDE DERIVATIVE | PFIZER LIMITED (GB) | 2013-02-14 | — | — | WO | disclosed |
| WO-2013021309-A1 | INTERMEDIATE AND PROCESS FOR THE PREPARATION OF A SULFONAMIDE DERIVATIVE | PFIZER LIMITED (GB) | 2013-02-14 | — | — | WO | disclosed |
| US-8013019-B2 | Sulfonamide derivatives for the treatment of diseases | PFIZER INC (US) | 2011-09-06 | — | — | US | disclosed |
| US-8013019-B2 | Sulfonamide derivatives for the treatment of diseases | PFIZER INC (US) | 2011-09-06 | — | — | US | disclosed |
| US-8013019-B2 | Sulfonamide derivatives for the treatment of diseases | PFIZER INC (US) | 2011-09-06 | — | — | US | disclosed |
| US-20110152290-A1 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2011-06-23 | — | — | US | disclosed |
| EP-2303270-A1 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | Sanofi-aventis (FR) | 2011-04-06 | — | — | EP | disclosed |
| US-20100273758-A1 | Sulfonamide Derivatives For The Treatment Of Diseases | BROWN ALAN DANIEL | 2010-10-28 | — | — | US | disclosed |
| US-20050215590-A1 | Formamide derivatives for the treatment of diseases | PFIZER LIMITED (GB) | 2005-09-29 | — | — | US | disclosed |
| WO-2005090287-A2 | PHENYLETHANOLAMINE DERIVATIVES AS BETA-2 AGONISTS | PFIZER LIMITED (GB) | 2005-09-29 | — | — | WO | disclosed |
| EP-1577291-A1 | Phenylethanolamine derivatives as beta-2 agonists | Pfizer Limited (GB) | 2005-09-21 | — | — | EP | disclosed |
| EP-1574501-A1 | Quinolinone derivatives, pharmaceutical compositions containing them and their use | Pfizer Limited (GB) | 2005-09-14 | — | — | EP | disclosed |
| WO-2005080324-A1 | SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER LIMITED (GB) | 2005-09-01 | — | — | WO | disclosed |
| WO-2005080313-A2 | SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER LIMITED (GB) | 2005-09-01 | — | — | WO | disclosed |
| US-20050182091-A1 | For therapy of asthma or chronic obstructive pulmonary disease (COPD) in a mammal | PFIZER INC. | 2005-08-18 | — | — | US | disclosed |
| US-20050171147-A1 | Sulfonamide derivatives for the treatment of diseases | PFIZER INC. | 2005-08-04 | — | — | US | disclosed |
| US-20050014763-A1 | 2-Amino-pyridine derivatives useful for the treatment of diseases | PFIZER INC | 2005-01-20 | — | — | US | disclosed |
| WO-2004108676-A1 | 2-(6-AMINO-PYRIDIN-3-YL)-2-HYDROXYETHYLAMINE DERIVATIVES AS BETA 2-ADRENOCEPTORS AGONISTS | PFIZER LIMITED (GB) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014763-A1 | 2-Amino-pyridine derivatives useful for the treatment of diseases | PAH, AADAT, IL4I1 | CYP1A2 26/4885CYP2C19 130/4885AKR1B1 256/4885 |
| US-20100273758-A1 | Sulfonamide Derivatives For The Treatment Of Diseases | SULT2A1, STS, SULT1A1 | CYP1A2 61/4885CYP2C19 137/4885AKR1B1 168/4885 |
| US-20050182091-A1 | For therapy of asthma or chronic obstructive pulmonary disease (COPD) in a mammal | LTC4S, LTB4R2, LTB4R | CYP1A2 142/4885CYP2C19 560/4885AKR1B1 208/4885 |
| US-20110152290-A1 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | EDF1, LPAR2, LIPG | CYP1A2 1341/4885CYP2C19 2748/4885AKR1B1 960/4885 |
| US-20050171147-A1 | Sulfonamide derivatives for the treatment of diseases | SULT2A1, STS, SULT1A1 | CYP1A2 61/4885CYP2C19 137/4885AKR1B1 168/4885 |
| US-20050215590-A1 | Formamide derivatives for the treatment of diseases | FH, FAH, HRH4 | CYP1A2 25/4885CYP2C19 163/4885AKR1B1 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.